Dr. Pherson Faces DEA Decree: Another Day in Reg Hell
Published Date: 8/20/2025
Notice
Summary
Kenneth Pherson, D.O., lost his DEA registration because he no longer has permission to handle controlled substances in Florida. He didn’t ask for a hearing after being notified, so the DEA moved forward and officially revoked his registration. This means Dr. Pherson can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Pherson
DEA Certificate of Registration No. FP0455142 issued to Kenneth Pherson, D.O., is revoked and any pending applications to renew, modify, or obtain registration in Florida are denied. The Order is effective September 19, 2025, after the Agency found his Florida osteopathic medical license suspended on or about August 29, 2024, and he did not request a hearing following the December 2, 2024 Order to Show Cause.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2025-15866 — Andrew Konen, M.D.; Decision and Order
Dr. Andrew Konen from Dallas lost his DEA license because he wrote lots of prescriptions for strong drugs in ways that weren’t legal or safe. He didn’t show up to defend himself, so the government decided to revoke his registration and deny any future applications. This means he can’t legally prescribe controlled substances anymore, starting now.
Next: 2025-15868 — Transcontinental Gas Pipe Line Company, LLC; Notice of Request for Extension of Time
Transcontinental Gas Pipe Line Company (Transco) asked for more time to finish its Central Louisiana Abandonment Project offshore Louisiana, pushing the deadline from September 3, 2025, to December 31, 2026. They ran into problems like bad weather and limited vessel availability, which slowed things down. This affects anyone following the project timeline and could delay related plans, but no new costs were mentioned yet.